Sanofi shows off pos­i­tive PhI­II tri­al re­sults for Tou­jeo, open­ing the door to a new group of di­a­betes pa­tients

A lit­tle un­der two months since their lat­est set­back in di­a­betes R&D as their dom­i­nant perch in the mar­ket is shak­en by se­vere head­winds, Sanofi had some pos­i­tive re­sults to re­port Mon­day from a Phase III tri­al ap­ply­ing its Lan­tus in­sulin fol­lowup in child­hood and ado­les­cent type 1 di­a­betes.

Com­par­ing 223 pa­tients giv­en Tou­jeo (in­sulin glargine 300 units/mL) for 26 weeks against a con­trol arm giv­en the base­line Lan­tus treat­ment (in­sulin glargine 100 units/mL), Sanofi found com­pa­ra­ble rates of sev­er­al types of hy­po­glycemic events. The pa­tients were aged 6 to 17. The re­sults earned Sanofi a CHMP pos­i­tive opin­ion for ex­pand­ing Tou­jeo to T1 di­a­betes pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER